Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2011.01.010PMID 21330148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Zoledronic acid

  2012cited by this paper
• Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

  2011influential reference
• RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Zoledronic-acid

  2011cited by this paper
• Invasive breast cancer.

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• Should liver metastases of breast cancer be biopsied to improve treatment choice?

  2011cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

  2011influential reference
• Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

  2010cited by this paper
• The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.

  2010cited by this paper
• Abstract S1-1: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer

  2010cited by this paper
• A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

  2010cited by this paper
• Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

  2010cited by this paper
• Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane

  2010cited by this paper
• Discordance in hormone receptor status in breast cancer during tumor progression.

  2010cited by this paper
• A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).

  2010cited by this paper
• Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.

  2010cited by this paper
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Abstract S1-3: A Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the ‘FIRST’ Study

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis

  2009cited by this paper
• RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC).

  2009cited by this paper
• Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

  2009cited by this paper
• Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2009cited by this paper
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  2009cited by this paper
• SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).

  2009cited by this paper
• RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

  2009cited by this paper
• Relationship of Anthracycline-Free Interval to Outcomes in a Phase 3 Trial of Pegylated Liposomal Doxorubicin Plus Docetaxel Compared with Docetaxel Monotherapy in Patients with Advanced Breast Cancer Treated with Adjuvant Anthracycline.

  2009cited by this paper
• Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).

  2009cited by this paper
• Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

  2009cited by this paper
• Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

  2009cited by this paper
• First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer

  2009cited by this paper
• Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium.

  2009cited by this paper
• Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.

  2009cited by this paper
• Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

  2009cited by this paper
• Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

  2009cited by this paper
• Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial

  2009cited by this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009cited by this paper
• Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study.

  2009cited by this paper
• Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC)

  2009cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

  2009cited by this paper
• Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

  2008cited by this paper
• Optimal schedule of paclitaxel: weekly is better.

  2008cited by this paper
• Locally advanced breast cancer

  2008cited by this paper
• Guidelines for International Breast Health and Cancer Control – Implementation Supplement to Cancer Guideline Implementation for Breast Healthcare in Low-Income and Middle-Income Countries Overview of the Breast Health Global Initiative Global Summit 2007

  2008cited by this paper
• Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

  2008cited by this paper
• Guidelines for International Breast Health and Cancer Control – Implementation Supplement to Cancer Guideline Implementation for Breast Healthcare in Low-and Middle-Income Countries Diagnosis Resource Allocation

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.

  2008cited by this paper
• Guidelines for International Breast Health and Cancer Control – Implementation Supplement to Cancer Guideline Implementation for Breast Healthcare in Low-and Middle-Income Countries : Treatment Resource Allocation

  2008cited by this paper
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

  2008cited by this paper
• Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.

  2008cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Platinum-based chemotherapy in triple-negative breast cancer.

  2008cited by this paper
• Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

  2008cited by this paper
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2008cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• Selective Targeting of Cancer Stem Cells

  2007cited by this paper
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

  2007cited by this paper
• Do ut des

  2007cited by this paper
• The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™

  2007cited by this paper
• Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2007cited by this paper
• Perspective of trastuzumab treatment

  2007cited by this paper
• Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

  2007cited by this paper
• Invasive breast cancer.

  2007cited by this paper
• Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis.

  2006cited by this paper
• Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

  2006cited by this paper
• PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

  2006cited by this paper
• Predicting a local recurrence after breast-conserving therapy by gene expression profiling

  2006cited by this paper
• Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer.

  2006cited by this paper
• Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.

  2006cited by this paper
• p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

  2006influential reference
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.

  2005cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Prognostic and predictive factors revisited.

  2005cited by this paper
• Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer

  2004cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.

  2004cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Is breast cancer survival improving?

  2004cited by this paper
• Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

  2004cited by this paper
• CNS metastases in breast cancer.

  2004cited by this paper
• A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases

  2003cited by this paper

• PEGylated pH-Responsive Liposomes for Enhancing the Intracellular Uptake and Cytotoxicity of Paclitaxel in MCF-7 Breast Cancer Cells

  2024cites this paper
• Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study

  2023cites this paper
• Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy.

  2022cites this paper
• Permissive role of Na+/H+ exchanger isoform 1 in migration and invasion of triple-negative basal-like breast cancer cells

  2022cites this paper
• Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

  2021cites this paper
• A multistage oral delivery system of PTX for improving oral bioavailability and enhancing anticancer efficacy

  2021cites this paper
• Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer

  2020cites this paper
• Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer

  2020cites this paper
• LINC00309 is associated with short disease-free survival in breast cancer

  2019cites this paper
• Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.

  2019cites this paper
• Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases

  2019cites this paper
• Synthesis of C1–C11 eribulin fragment and its diastereomeric analogues

  2019cites this paper
• Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients

  2018cites this paper
• The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an in vitro and in vivo evaluation

  2018cites this paper
• In vivo validation of metastasis-regulating microRNA-766 in human triple-negative breast cancer cells

  2017cites this paper
• Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer

  2017cites this paper
• A Review of Novel Approaches to Enhance Efficacy of Medical Treatment ofHormone Receptor Positive, Her2 Negative Breast Cancer

  2017cites this paper
• SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer

  2016cites this paper
• Eribulin in heavily pretreated metastatic breast cancer: A tertiary care center experience from India.

  2016cites this paper
• Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.

  2016cites this paper
• IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells

  2016cites this paper
• GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

  2016cites this paper
• RAS pathway biomarkers for breast cancer prognosis.

  2016cites this paper
• Oncological and Palliative Care for Patients with Lung Cancer and Patients with Breast Cancer: Two Opposite Ends of a Spectrum

  2015cites this paper
• Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways

  2015cites this paper
• Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

  2015cites this paper
• The Role of Mechanism of Action of CD200:CD200R1 Interaction in Breast Cancer

  2015cites this paper
• Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute

  2015cites this paper
• Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.

  2015cites this paper
• Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.

  2015cites this paper
• Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting

  2015cites this paper
• Pattern of metastasis and outcome in patients with breast cancer

  2015cites this paper
• Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

  2014cites this paper
• Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL

  2014cites this paper
• Selective anticancer copper(II)-mixed ligand complexes: targeting of ROS and proteasomes.

  2014cites this paper
• PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

  2014cites this paper
• Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.

  2014cites this paper
• New Therapies and Functional-Molecular Imaging

  2014cites this paper
• Universitet TIMP-1 and responsiveness to gemcitabine in advanced breast cancer

  2014cites this paper
• Implication de réseaux de récepteurs membranaires dans la signalisation du NGF et de son précurseur dans les cellules cancéreuses de sein

  2014cites this paper
• Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

  2014cites this paper
• TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

  2014cites this paper
• Eribulin mesylate: A new therapeutic option for metastatic breast cancer

  2013cites this paper
• A new emergency in oncology: Bone metastases in breast cancer patients (Review)

  2013cites this paper
• A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model

  2013cites this paper
• Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells

  2013cites this paper
• Management of Malignant Pleural Effusion

  2013cites this paper
• O CANCRO DA MAMA METASTIZADO É CURÁVEL? A PROPÓSITO DE UM CASO CLÍNICO

  2013cites this paper
• Perspectives des thérapies ciblées dans le cancer du sein métastatique

  2012cites this paper
• [Targeted based therapies in metastatic breast cancer: future evolution].

  2012cites this paper
• Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.

  2012cites this paper
• Targeted agents in second-line bladder cancer therapy

  2012cites this paper
• Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy

  2012cites this paper
• Management of bone metastases in breast cancer

  2012cites this paper
• Target therapy in elderly breast cancer patients.

  2012cites this paper
• Advances in the management of metastatic breast cancer : options beyond first-line chemotherapy

  2012cites this paper
• Novel oncologic drugs: what they do and how they affect images.

  2011cites this paper